Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
21/12/18	British shares falter as Fed, oil play Scrooge	RE
20/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
19/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
18/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
08/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
06/12/18	FTSE : falls as growth angst spreads	RE
06/12/18	Growth and trade nerves grind European shares down to two-week low	RE
06/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
08/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
08/01/19	Shire : Form 8.3 -	PU
08/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
08/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
06/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE	+2.42%	-.--%	-	-	0
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+163.68%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.50%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+82.78%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+31.03%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+41.41%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.74%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-39.57%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.87%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.52%	161B
Average	+0.68%	+1.33%	+26.20%	+53.11%	404.83B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+79.10%

Shire Stock

Stocks

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Quotes and Performance

Other Pharmaceuticals

Company Profile